https://academic.oup.com/edrv/article/44/3/417/6889555
Bone Turnover Markers: Basic Biology to Clinical Applications
The current recommendation is that treatment with oral bisphosphonates should continue for 5 years and intravenous bisphosphonate for 3 years. After this period, a pause in treatment should be considered. It has been shown that bisphosphonates have this distinct characteristic which other anti-osteoporosis medications do not have; they can accumulate in the skeleton and can still provide benefit to the bones even when treatment is stopped (312, 313). Moreover, after discontinuing treatment, the antifracture efficacy persists (314). Long-term treatment with bisphosphonates has been related to rare side effects like atypical femoral fractures and osteonecrosis of the jaw and their risk may be minimized by discontinuing treatment (302). The discontinuation of bisphosphonates has been associated with rapid decreases in the risk of atypical femoral fractures (315). Continuation for a duration greater than the one described above (ie, 10 years for oral bisphosphonates and 6 years for intravenous ones) should be considered in high-risk patients (vertebral or hip fracture, T-score below −2.5) (316).
이 글은 네이버 블로그에서 가져온 글입니다. 원문: blog.naver.com/surgeon
답글 남기기